

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



## Summary of Financial Statements for the Fiscal Year Ended March 31, 2024 [IFRS] (Consolidated)



May 7, 2024

Company name: JMDC Inc.  
 Listing: Tokyo Stock Exchange  
 Stock code: 4483  
 URL: <https://www.jmdc.co.jp/en/>  
 Representative: Ryo Noguchi, President and CEO  
 Inquiries: Tomohiro Mochizuki, Executive Officer and CFO  
 TEL: +81-3-5733-5010  
 Scheduled date to hold an Ordinary General Meeting of Shareholders: June 25, 2024  
 Scheduled date to commence dividend payments: June 6, 2024  
 Scheduled date to file a Securities Report: June 26, 2024  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results presentation meeting: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated financial results for the fiscal year ended March 31, 2024 (from April 1, 2023 to March 31, 2024)

#### (1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended								
March 31, 2024	32,381	16.4	7,006	18.2	6,907	17.6	4,627	8.2
March 31, 2023	27,809	27.5	5,926	23.9	5,876	23.2	4,274	31.8

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
	Millions of yen	%	Millions of yen	%	Yen	Yen
Fiscal year ended						
March 31, 2024	4,607	8.0	4,631	7.7	71.76	69.95
March 31, 2023	4,267	31.4	4,299	32.4	71.17	67.69

	Equity attributable to owners of parent	Total assets	Revenue
	Profit ratio	Ratio of profit (loss) before tax	Operating profit ratio
Fiscal year ended	%	%	%
March 31, 2024	6.8	6.3	21.6
March 31, 2023	8.9	7.3	21.3

Reference: Equity method profit (loss) Fiscal year ended March 31, 2024 ¥0 million  
 Fiscal year ended March 31, 2023 ¥- million  
 EBITDA Fiscal year ended March 31, 2024 ¥9,471 million [22.7%]  
 Fiscal year ended March 31, 2023 ¥7,716 million [20.4%]

Note: EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses

## (2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent	Owners' equity per share
As of	Millions of yen	Millions of yen	Millions of yen	%	Yen
March 31, 2024	122,452	70,686	70,590	57.6	1,080.51
March 31, 2023	98,567	64,524	64,539	65.5	1,025.89

## (3) Consolidated cash flows

	Cash flows from (used in) operating activities	Cash flows from (used in) investing activities	Cash flows from (used in) financing activities	Cash and cash equivalents balance at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2024	(17)	(24,864)	16,581	14,473
March 31, 2023	4,062	(22,769)	28,296	22,782

## 2. Cash dividends

	Annual dividends					Total dividend (Total)	Payout ratio (Consolidated)	Ratio of owners' equity to gross assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
Fiscal year ended March 31, 2023	Yen —	Yen —	Yen —	Yen 12.00	Yen 12.00	Millions of yen 754	% 16.9	% 1.5
Fiscal year ended March 31, 2024	—	—	—	14.00	14.00	914	19.5	1.3
Fiscal year ending March 31, 2025 (Forecast)	—	—	—	—	—		—	

Note: The Company has decided that the year-end dividend per share for the fiscal year ended March 31, 2024 shall be ¥14. For more details, please refer to "Notice Concerning Dividends of Surplus" released on May 7, 2024.

## 3. Consolidated earnings forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2025	43,000	32.8	9,300	32.7	9,100	31.7	6,200	34.0	6,200	34.6	94.90

Reference: EBITDA Fiscal year ending March 31, 2025 ¥12,000 million [26.7%]

**\* Notes**

- (1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None
- (2) Changes in accounting policies and changes in accounting estimates
- (i) Changes in accounting policies required by IFRS: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at end of the period (including treasury shares)

As of March 31, 2024	65,331,208 shares
As of March 31, 2023	62,910,608 shares

(ii) Number of treasury shares at end of the period

As of March 31, 2024	647 shares
As of March 31, 2023	574 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2024	64,204,940 shares
Fiscal year ended March 31, 2023	59,965,644 shares

(Reference) Outline of non-consolidated financial results

**1. Non-consolidated financial results for the fiscal year ended March 31, 2024 (from April 1, 2023 to March 31, 2024)**

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Ordinary profit (loss)		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended								
March 31, 2024	11,474	21.9	1,877	(6.4)	1,916	5.5	(429)	—
March 31, 2023	9,409	17.2	2,006	23.8	1,816	6.8	1,323	9.3

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
March 31, 2024	(6.69)	—
March 31, 2023	22.08	21.00

Note: Information on diluted earnings per share for the fiscal year ended March 31, 2024 is not presented since, although potential shares did exist, the recorded figure was a basic loss per share.

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2024	90,867	60,867	67.0	931.64
March 31, 2023	73,222	59,843	81.7	950.74

Reference: Equity As of March 31, 2024 ¥60,836 million  
As of March 31, 2023 ¥59,811 million

\* **Financial results reports are exempt from audits conducted by certified public accountants or an audit corporation.**

\* **Proper use of earnings forecasts, and other special items**

Notes on forward-looking statements

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to page 5 of the attached materials.

How to obtain supplementary documents on financial results

Supplementary documents on financial results are released via TDnet on the same day.

## Attached Material Index

1. Outline of business performance .....	2
(1) Outline of business performance for the fiscal year under review .....	2
(2) Outline of financial position for the fiscal year under review .....	4
(3) Outline of cash flows for the fiscal year under review .....	4
(4) Future outlook .....	5
2. Basic approach to the selection of accounting principles .....	5
3. Consolidated financial statements and significant notes thereto.....	6
(1) Consolidated statement of financial position.....	6
(2) Consolidated statement of profit or loss.....	7
(3) Consolidated statement of comprehensive income .....	8
(4) Consolidated statement of changes in equity .....	9
(5) Consolidated statement of cash flows .....	11
(6) Notes concerning the consolidated financial statements .....	12
Notes on going concern assumption.....	12
Segment information, etc. ....	12
Information per share .....	14
Significant subsequent events.....	14

## 1. Outline of business performance

### (1) Outline of business performance for the fiscal year under review

JMDC Inc. (the “Company”) is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.

In the Healthcare-Big Data segment, to promote the health services for payers, centered on health insurance associations, we provide analysis services for data held by payers as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.

In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.

In the Dispensing Pharmacy Support segment, we develop and sell systems such as receipt computers and electronic medication history systems to health insurance pharmacies.

The Company’s financial results for the fiscal year ended March 31, 2024, were as follows.

(Operating results)

(Millions of yen)

Category	10th fiscal year (From April 1, 2022 to March 31, 2023)	11th fiscal year (From April 1, 2023 to March 31, 2024)	YoY change	
Revenue	27,809	32,381	4,571	16.4%
Operating profit	5,926	7,006	1,079	18.2%
EBITDA [margin]	7,716 [27.7%]	9,471 [29.3%]	1,755	22.7%

(Segment results)

(Millions of yen)

Category		10th fiscal year (From April 1, 2022 to March 31, 2023)	11th fiscal year (From April 1, 2023 to March 31, 2024)	YoY change	
Healthcare-Big Data	Segment revenue	19,221	25,058	5,836	30.4%
	Segment profit [ratio]	6,137 [31.9%]	7,886 [31.5%]	1,748	28.5%
Tele-medicine	Segment revenue	5,038	5,579	540	10.7%
	Segment profit [ratio]	1,768 [35.1%]	2,075 [37.2%]	306	17.4%
Dispensing Pharmacy Support	Segment revenue	3,826	1,859	(1,967)	(51.4%)
	Segment profit [ratio]	459 [12.0%]	229 [12.3%]	(230)	(50.1%)
Adjustment	Segment revenue	(277)	(115)	162	–
	Segment profit	(649)	(719)	(70)	–
Total	Revenue	27,809	32,381	4,571	16.4%
	EBITDA [margin]	7,716 [27.7%]	9,471 [29.3%]	1,755	22.7%

(Note) EBITDA is an objective indicator for judging the achievement of the JMDC Group’s (the “Group’s”) management policies and strategies or management objectives. The Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to assess the Group’s performance more effectively. The formulas for calculating EBITDA and EBITDA margin are as follows.

- EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- EBITDA margin: EBITDA / Revenue x 100

#### Healthcare-Big Data

The Group possesses the largest scale of healthcare big data in Japan that is available for public through data anonymization of receipts (admitted patients, day patients, prescriptions), medical examinations and member records received from health insurance associations. During the fiscal year ended March 31, 2024, the number of contracted health insurance associations and the annual transaction value per

customer at pharmaceutical and insurance companies which the Company uses and utilizes, each continued to increase on a year-on-year basis, and the business is continuing to expand.

Moreover, the Pep Up health information platform developed by the Company is used to generate individualized advice and display risk of diseases for every individual user based on the above healthcare-big data. The number of IDs issued for Pep Up continued to expand during the fiscal year ended March 31, 2024.

In addition to the above-mentioned business expansion, the Company gathered 148 companies and organizations that will work to implement health management that exceeds industry organizations, and commenced full-scale operations for the “Health & Productivity Management Alliance” in June 2023, expanding to 373 companies and organizations as of March 31, 2024 and achieving the objective of 300 companies and organizations for the first year. The mission of this alliance is to revitalize Japanese companies through the health of employees and enable the sustainability of the health insurance system, and it is currently promoting three initiatives to hold study sessions and seminars, create health management assessments based on surveys and data analysis, and build information platforms for health management solutions. Going forward, the Company will accelerate the creation of results and business, by further expanding the activities and implementing health management.

During the fiscal year ended March 31, 2024, the Company made Cancerscan Inc. its subsidiary. The Company will further accelerate the expansion of the Group’s business in the Payers/Individuals fields by developing services and solutions that the Company has cultivated through transactions with health insurance unions through Cancerscan’s strong client base in local governments, and by providing solutions, such as lifestyle-related disease treatment programs developed by applying Cancerscan’s strength in behavioral modification know-how, to the health insurance unions and companies that are the Company’s clients.

As a result, segment revenue for the fiscal year ended March 31, 2024 was ¥25,058 million and segment profit (segment EBITDA) was ¥7,886 million.

#### Tele-medicine

The Group has the biggest platform for radiologists in Japan. During the fiscal year ended March 31, 2024, revenue increased on a year-on-year basis as a result of the increase in the number of medical institutions utilizing remote image interpretation services.

We continue to take measures to expand our business, including adding functions to “AI-RAD,” an artificial intelligence engine platform that assists in diagnostic imaging, and preparations for full-scale business development in Asia.

As a result, segment revenue for the fiscal year ended March 31, 2024 was ¥5,579 million and segment profit (segment EBITDA) was ¥2,075 million.

#### Dispensing Pharmacy Support

During the fiscal year ended March 31, 2024, we worked to cultivate new customers while securing replacement demand from existing customers. In the environment surrounding dispensing pharmacies, the intensity of competition has increased as digitalization has advanced.

Amid the above-mentioned situation, the Company transferred all shares of Unike Software Research Co., Ltd., a component of the Company’s Dispensing Pharmacy Support segment, and its management purpose company to the Company’s business partner EM Systems Co., Ltd. in June 2023. Due to this transfer, the Company will provide even higher quality services by further acceleration initiatives taken thus far by both companies, and make a splash in the pharmacy market, which will increase the Company’s market share.

As a result, segment revenue for the fiscal year ended March 31, 2024 was ¥1,859 million and segment profit (segment EBITDA) was ¥229 million.

As a result of the above, for the fiscal year ended March 31, 2024, revenue increased to ¥32,381 million, operating profit to ¥7,006 million, and EBITDA to ¥9,471 million. Adjustments to reconcile EBITDA to operating profit are as follows.

(Reconciliation of EBITDA to operating profit)

	(Millions of yen)	
	10th fiscal year (From April 1, 2022 to March 31, 2023)	11th fiscal year (From April 1, 2023 to March 31, 2024)
EBITDA	7,716	9,471
Depreciation and amortization	(2,016)	(2,237)
Other income	275	1,555
Other expenses	(49)	(1,783)
Operating profit	5,926	7,006

## (2) Outline of financial position for the fiscal year under review

### Assets

Assets at the end of the fiscal year under review were ¥122,452 million, an increase of ¥23,885 million compared with the end of the fiscal year ended March 31, 2023. This was mainly due to an increase of ¥10,932 million in trade and other receivables as a result of business expansion and an increase of ¥16,150 million in goodwill mainly as a result of the acquisition of shares of Cancerscan Inc. (making it a subsidiary). Cash and cash equivalents decreased by ¥8,308 million. For details regarding the changes in cash and cash equivalents, please refer to “(3) Outline of cash flows for the fiscal year under review.”

### Liabilities

Liabilities at the end of the fiscal year under review were ¥51,765 million, an increase of ¥17,723 million compared with the end of the fiscal year ended March 31, 2023. This was mainly due to an increase of ¥21,358 million in borrowings in current liabilities.

### Equity

Equity at the end of the fiscal year under review was ¥70,686 million, an increase of ¥6,162 million compared with the end of the fiscal year ended March 31, 2023. This was mainly due to an increase in retained earnings due to the recording of ¥4,607 million in profit attributable to owners of parent, as well as an increase of ¥1,105 million in both share capital and additional paid-in capital as a result of the exercise of share acquisition rights.

## (3) Outline of cash flows for the fiscal year under review

Cash and cash equivalents (“cash”) at the end of the fiscal year under review was ¥14,473 million, a decrease of ¥8,308 million compared with the end of the fiscal year ended March 31, 2023.

Cash flows and factors affecting them for the fiscal year under review were as follows.

### Cash flows from operating activities

Net cash used in operating activities was ¥17 million (¥4,062 million provided in the previous fiscal year). This was primarily due to the recording of an increase of ¥6,675 million in trade and other receivables as a result of business expansion, and ¥2,317 million in income taxes paid despite recording ¥6,907 million in profit before tax, and ¥2,237 million in depreciation and amortization.

### Cash flows from investing activities

Net cash used in investing activities was ¥24,864 million (¥22,769 million used in the previous fiscal year). This was primarily due to purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥20,176 million, purchase of investments of ¥2,572 million, purchase of property, plant and equipment of ¥893 million, and purchase of intangible assets of ¥1,365 million.



**Cash flows from financing activities**

Net cash provided by financing activities was ¥16,581 million (¥28,296 million provided by the previous fiscal year). This was primarily due to the recording of ¥16,402 million in proceeds from short-term borrowings.

**(4) Future outlook**

The Group will likely post increased revenue and profit for the fiscal year ending March 31, 2025.

**(i) Healthcare-Big Data**

The Company expects the further expansion of business performance as a result of developing measures for the various players associated with healthcare by creating high value-added data utilization services and expanding data types. In addition, by making Cancerscan Inc. a subsidiary, the Company expects to significantly expand the scale of its business in the local governments area. On the other hand, the Company will continue to make proactive up-front investments for future growth in order to establish a data environment in the major areas of healthcare in Japan.

**(ii) Tele-medicine**

The business performance will likely continue to expand by further strengthening and increasing the operational efficiency of remote image diagnostic support services, and capturing the remote image interpretation needs at medical institutions. Furthermore, the Company is looking into the expansion of the content of services for medical institutions, such as the utilization of AI, as well as the development of business overseas.

**(iii) Dispensing Pharmacy Support**

Earnings are expected to remain firm as a result of the utilization of synergy within the Group and enhancement of sales.

As for the Group's consolidated financial results, we forecast ¥43,000 million in revenue (an increase of ¥10,618 million year on year), ¥9,300 million in operating profit (an increase of ¥2,293 million year on year), ¥9,100 million in profit before tax (an increase of ¥2,192 million year on year) and ¥ 6,200 million in profit attributable to owners of parent (an increase of ¥1,592 million year on year). EBITDA, which the Company deems to be an important business indicator, is forecast at ¥12,000 million (an increase of ¥2,528 million year on year).

The above-mentioned outlook is based on judgments and assumptions derived from information that is currently available to the Company, and the actual business performance in the future may differ significantly due to changes in the situation.

**2. Basic approach to the selection of accounting principles**

Starting from the fiscal year ended March 31, 2019, the Group began to voluntarily adopt the International Financial Reporting Standards (IFRS) instead of Japanese GAAP in order to make its financial statements more comparable internationally in capital markets and unify the Group's accounting practices.

### 3. Consolidated financial statements and significant notes thereto

#### (1) Consolidated statement of financial position

(Millions of yen)

	As of March 31, 2023	As of March 31, 2024
<b>Assets</b>		
Current assets		
Cash and cash equivalents	22,782	14,473
Trade and other receivables	11,241	22,173
Other financial assets	3,340	3,619
Inventories	275	249
Other current assets	601	879
Total current assets	38,240	41,395
Non-current assets		
Property, plant and equipment	10,772	12,724
Goodwill	39,824	55,974
Intangible assets	5,922	5,768
Other financial assets	1,597	4,541
Deferred tax assets	2,057	1,771
Other non-current assets	152	277
Total non-current assets	60,326	81,057
Total assets	98,567	122,452
<b>Liabilities and equity</b>		
Liabilities		
Current liabilities		
Borrowings	994	22,352
Trade and other payables	5,790	5,975
Lease liabilities	846	1,086
Income taxes payable	1,201	1,316
Contract liabilities	2,066	1,462
Other current liabilities	1,317	2,041
Total current liabilities	12,216	34,235
Non-current liabilities		
Borrowings	11,935	6,574
Lease liabilities	6,623	7,819
Retirement benefit liability	322	205
Provisions	692	472
Deferred tax liabilities	730	699
Contract liabilities	1,520	1,535
Other non-current liabilities	—	223
Total non-current liabilities	21,825	17,530
Total liabilities	34,042	51,765
Equity		
Share capital	23,994	25,099
Capital surplus	27,211	28,304
Treasury shares	(2)	(3)
Other components of equity	28	23
Retained earnings	13,308	17,166
Total equity attributable to owners of parent	64,539	70,590
Non-controlling interests	(14)	96
Total equity	64,524	70,686
Total liabilities and equity	98,567	122,452

**(2) Consolidated statement of profit or loss**

(Millions of yen)

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
Revenue	27,809	32,381
Cost of sales	11,950	13,128
Gross profit	15,859	19,252
Selling, general and administrative expenses	10,158	12,017
Other income	275	1,555
Other expenses	49	1,783
Operating profit	5,926	7,006
Finance income	38	16
Finance costs	88	114
Share of profit (loss) of investments accounted for using equity method	–	0
Profit before tax	5,876	6,907
Income tax expense	1,601	2,280
Profit	4,274	4,627
Profit attributable to		
Owners of parent	4,267	4,607
Non-controlling interests	6	19
Profit	4,274	4,627
Earnings per share		
Basic earnings per share (Yen)	71.17	71.76
Diluted earnings per share (Yen)	67.69	69.95

**(3) Consolidated statement of comprehensive income**

(Millions of yen)

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
Profit	4,274	4,627
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	3	5
Remeasurements of defined benefit plans	21	-
Total of items that will not be reclassified to profit or loss	25	5
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(0)	(1)
Total of items that may be reclassified to profit or loss	(0)	(1)
Other comprehensive income, net of tax	25	3
Comprehensive income	4,299	4,631
Comprehensive income attributable to		
Owners of parent	4,292	4,611
Non-controlling interests	6	19
Comprehensive income	4,299	4,631

**(4) Consolidated statement of changes in equity**

Fiscal year ended March 31, 2023 (from April 1, 2022 to March 31, 2023)

(Millions of yen)

	Equity attributable to owners of parent					
	Share capital	Capital surplus	Treasury shares	Other components of equity		
				Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance as of April 1, 2022	9,091	12,483	(2)	(4)	–	–
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	(0)	3	21
Total comprehensive income	–	–	–	(0)	3	21
Issuance of share acquisition rights	–	–	–	–	–	–
Exercise of share acquisition rights	169	169	–	–	–	–
Forfeiture of share acquisition rights	–	0	–	–	–	–
Issuance of new shares	14,732	14,558	–	–	–	–
Purchase of treasury shares	–	–	(0)	–	–	–
Dividends	–	–	–	–	–	–
Increase (decrease) by business combination	–	–	–	–	–	–
Transfer to retained earnings	–	–	–	–	(3)	(21)
Total transactions with owners	14,902	14,728	(0)	–	(3)	(21)
Balance as of March 31, 2023	23,994	27,211	(2)	(4)	–	–

	Equity attributable to owners of parent					
	Other components of equity		Retained earnings	Total	Non-controlling interests	Total
	Share acquisition rights	Total				
Balance as of April 1, 2022	21	17	9,580	31,170	(5)	31,165
Profit	–	–	4,267	4,267	6	4,274
Other comprehensive income	–	25	–	25	–	25
Total comprehensive income	–	25	4,267	4,292	6	4,299
Issuance of share acquisition rights	13	13	–	13	–	13
Exercise of share acquisition rights	(2)	(2)	–	337	–	337
Forfeiture of share acquisition rights	(0)	(0)	–	–	–	–
Issuance of new shares	–	–	–	29,290	–	29,290
Purchase of treasury shares	–	–	–	(0)	–	(0)
Dividends	–	–	(565)	(565)	–	(565)
Increase (decrease) by business combination	–	–	–	–	(15)	(15)
Transfer to retained earnings	–	(25)	25	–	–	–
Total transactions with owners	10	(14)	(540)	29,075	(15)	29,059
Balance as of March 31, 2023	32	28	13,308	64,539	(14)	64,524

## Fiscal year ended March 31, 2024 (from April 1, 2023 to March 31, 2024)

(Millions of yen)

	Equity attributable to owners of parent					
	Share capital	Capital surplus	Treasury shares	Other components of equity		
				Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2023	23,994	27,211	(2)	(4)	–	32
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	(1)	5	–
Total comprehensive income	–	–	–	(1)	5	–
Issuance of share acquisition rights	–	–	–	–	–	6
Exercise of share acquisition rights	1,105	1,105	–	–	–	(8)
Forfeiture of share acquisition rights	–	0	–	–	–	(0)
Purchase of treasury shares	–	–	(0)	–	–	–
Dividends	–	–	–	–	–	–
Increase (decrease) by business combination	–	(13)	–	–	–	–
Transfer to retained earnings	–	–	–	–	(5)	–
Total transactions with owners	1,105	1,092	(0)	–	(5)	(2)
Balance as of March 31, 2024	25,099	28,304	(3)	(6)	–	30

	Equity attributable to owners of parent				
	Other components of equity	Retained earnings	Total	Non-controlling interests	Total
	Total				
Balance as of April 1, 2023	28	13,308	64,539	(14)	64,524
Profit	–	4,607	4,607	19	4,627
Other comprehensive income	3	–	3	–	3
Total comprehensive income	3	4,607	4,611	19	4,631
Issuance of share acquisition rights	6	–	6	–	6
Exercise of share acquisition rights	(8)	–	2,202	–	2,202
Forfeiture of share acquisition rights	(0)	–	–	–	–
Purchase of treasury shares	–	–	(0)	–	(0)
Dividends	–	(754)	(754)	–	(754)
Increase (decrease) by business combination	–	–	(13)	90	77
Transfer to retained earnings	(5)	5	–	–	–
Total transactions with owners	(8)	(749)	1,440	90	1,531
Balance as of March 31, 2024	23	17,166	70,590	96	70,686

**(5) Consolidated statement of cash flows**

(Millions of yen)

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
Cash flows from operating activities		
Profit before tax	5,876	6,907
Depreciation and amortization	2,016	2,237
Other income	(275)	(1,555)
Other expenses	49	1,783
Decrease (increase) in trade and other receivables	(1,394)	(6,675)
Decrease (increase) in inventories	(6)	(49)
Increase (decrease) in trade and other payables	(722)	275
Other	431	(558)
Subtotal	5,974	2,366
Interest and dividends received	0	14
Interest paid	(86)	(80)
Income taxes paid	(1,826)	(2,317)
Net cash provided by (used in) operating activities	4,062	(17)
Cash flows from investing activities		
Purchase of property, plant and equipment	(822)	(893)
Purchase of intangible assets	(1,118)	(1,365)
Payments for loans receivable	(790)	(264)
Collection of loans receivable	110	18
Purchase of investments	(192)	(2,572)
Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation	25	-
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(20,139)	(20,176)
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	-	273
Payments for sale of shares of subsidiaries resulting in change in scope of consolidation	-	(108)
Other	158	225
Net cash provided by (used in) investing activities	(22,769)	(24,864)
Cash flows from financing activities		
Proceeds from short-term borrowings	20,145	16,402
Repayments of short-term borrowings	(20,358)	(264)
Proceeds from long-term borrowings	1,810	2,528
Repayments of long-term borrowings	(1,439)	(2,606)
Repayments of lease liabilities	(859)	(931)
Proceeds from issuance of shares	29,212	-
Proceeds from exercise of share acquisition rights	337	2,202
Dividends paid	(564)	(754)
Other	12	5
Net cash provided by (used in) financing activities	28,296	16,581
Net increase (decrease) in cash and cash equivalents	9,589	(8,300)
Cash and cash equivalents at beginning of period	13,192	22,782
Effect of exchange rate changes on cash and cash equivalents	0	(8)
Cash and cash equivalents at end of period	22,782	14,473

**(6) Notes concerning the consolidated financial statements****Notes on going concern assumption**

Not applicable.

**Segment information, etc.****(1) Overview of reportable segments**

The Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are regularly reviewed by the Board of Directors to make decisions about managerial resources to be allocated to the segments and assess their performances. The Group considers similarities in the nature of the services it provides and has three reportable segments: "Healthcare-Big Data," "Tele-medicine," and "Dispensing Pharmacy Support."

The main businesses and main services included in each reportable segment are as follows.

Reportable segments	Main businesses	Main services
Healthcare-Big Data	Business for industry Business for payers and individuals Business for medical service providers	Development and provision of medical databases (receipts, pharmaceuticals, etc.) and analysis of medical big data
Tele-medicine	Tele-medicine business	Remote image interpretation matching service and ASP service for remote image interpretation system
Dispensing Pharmacy Support	Dispensing pharmacy support business	Development and sales of business systems for dispensing pharmacies

**(2) Computation method for the amount of revenue, profit or loss, and other items for each reporting segment**

The accounting methods for the reportable segments are the same as those described in the accounting policies. Intersegment revenues are based on negotiated transaction prices, taking into account market prices and production costs.

The profits of reporting segments are in EBITDA and formula for calculating is as follows.

EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses

**(3) Information on the amount of revenue, profit or loss, and other items for each reporting segment**

Fiscal year ended March 31, 2023 (from April 1, 2022 to March 31, 2023)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare- Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	19,138	5,038	3,631	27,809	–	27,809
Intersegment revenue	83	–	194	277	(277)	–
Total	19,221	5,038	3,826	28,087	(277)	27,809
Segment profit						
EBITDA	6,137	1,768	459	8,366	(649)	7,716
Other items						
Depreciation and amortization	1,407	344	263	2,015	0	2,016

Note: Adjustments include elimination of intersegment transactions and corporate expenses.



Fiscal year ended March 31, 2024 (from April 1, 2023 to March 31, 2024)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare- Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	24,993	5,579	1,808	32,381	–	32,381
Intersegment revenue	64	–	50	115	(115)	–
Total	25,058	5,579	1,859	32,496	(115)	32,381
Segment profit						
EBITDA	7,886	2,075	229	10,191	(719)	9,471
Other items						
Depreciation and amortization	1,681	420	135	2,236	0	2,237

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

A reconciliation of EBITDA to profit before tax is as follows.

(Millions of yen)

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
EBITDA	7,716	9,471
Depreciation and amortization	(2,016)	(2,237)
Other income	275	1,555
Other expenses	(49)	(1,783)
Operating profit	5,926	7,006
Finance income	38	16
Finance costs	(88)	(114)
Share of profit (loss) of investments accounted for using equity method	–	0
Profit before tax	5,876	6,907

#### (4) Information about products and services

A listing of the products and service categories was omitted, because they are identical to the reportable segments.

#### (5) Information by region

Information by region was omitted because over 90% of the Group's total revenue was generated in Japan and its non-current assets are nearly entirely located in the country.

#### (6) Information about major customers

Information about major customers was omitted as there are no parties accounting for 10% or more of revenue in the consolidated statement of profit or loss out of revenue from external customers.

**Information per share****(1) Basis for calculating the basic earnings per share**

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
Profit attributable to owners of parent (Millions of yen)	4,267	4,607
Profit not attributable to ordinary shareholders of parent (Millions of yen)	–	–
Used to calculate the basic earnings per share Profit (Millions of yen)	4,267	4,607
Weighted average of the number of ordinary shares (Thousands of shares)	59,966	64,205
Basic earnings per share (Yen)	71.17	71.76

**(2) Basis for calculating the diluted earnings per share**

	Fiscal year ended March 31, 2023	Fiscal year ended March 31, 2024
Used to calculate the basic earnings per share Profit (Millions of yen)	4,267	4,607
Profit adjustment (Millions of yen)	–	–
Used to calculate the diluted earnings per share Profit (Millions of yen)	4,267	4,607
Weighted average of the number of ordinary shares (Thousands of shares)	59,966	64,205
Increase in the number of ordinary shares		
Share acquisition rights (Thousands of shares)	3,085	1,663
Weighted average of the number of ordinary shares after dilution (Thousands of shares)	63,051	65,868
Diluted earnings per share (Yen)	67.69	69.95

**Significant subsequent events**

Not applicable.